Any current/future new fundraising through debt or equity?

Natco Pharma currently has Rs. 116 crores of debt, primarily comprising Rs. 40 crores EPC credit (non-prepayable) and Rs. 76 crores foreign discounting (self-liquidating). On a net debt basis, the company is effectively net cash with Rs. 2,004 crores in cash, listed shares, investments, and deposits. The debt is mainly for working capital, and management is not very concerned about it. There is no explicit mention of any planned new fundraising through debt or equity in the near future. The management is contemplating acquisitions and may consider buybacks depending on acquisition outcomes but

Any current/future capex/capital investment/strategic investment?

The company plans a maintenance CAPEX of around Rs. 300 crores to Rs. 350 crores annually, mainly to maintain current operations and build orders. No large new site constructions are planned currently. (Page 18) They are investing in complex generics, drug deliveries, oligopeptides, and CAR-T therapies as part of R&D and strategic innovation efforts. (Page 12) Considering acquisitions primarily in the Rest of World (RoW) markets to strengthen the base business. No specific deals closed yet, but looking actively over the next few years. (Pages 5, 18) Potential buyback considered if unable to

Future growth expectations in sales/revenue/volumes?

Targeting 15% to 20% top-line (sales/revenue) growth for FY '25 and beyond, with optimism to sustain this trajectory assuming no significant surprises. Business aims to achieve approximately 20% profit growth alongside revenue growth. Plans to triple the agrochemical business to Rs. 300 crores in the next 2-3 years. Strategic focus on niche Para-IV filings to secure 2 to 3 successful first-to-file products in next 2 years. Geographic expansion and acquisitions, particularly in Rest of World (RoW) markets, are key pillars to drive future growth. Continued investment in complex generics, oligope

Future growth expectations in earnings/operating earnings/profits/EPS?

Natco expects more than 20% growth in earnings/profits for FY '25 given no major surprises. Management is optimistic about achieving 15%+ top-line growth and around 20% profit growth. Stable margins are anticipated if the product mix holds up over the next 1-2 years. The base business PAT is expected to be around Rs. 200-250 crores annually, consistent with earlier guidance. Natco aims to reinvent growth through niche Para-IV filings, geographic expansion, and acquisitions. The Agrochemical business targets a 3x growth to Rs. 300 crores in the next 3 years. The company anticipates sustaining R

Natco Pharma LtdQ4 FY24Pharmaceuticals & Biotechnology

Natco Pharma Ltd Q4 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹800.85P/E: 13.7Market Cap: ₹15.7K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 2

Targeting 15% to 20% top-line (sales/revenue) growth for FY '25 and beyond, with optimism to sustain this trajectory assuming no significant surprises.
Business aims to achieve approximately 20% profit growth alongside revenue growth.
Plans to triple the agrochemical business to Rs. 300 crores in the next 2-3 years.
Strategic focus on niche Para-IV filings to secure 2 to 3 successful first-to-file products in next 2 years.
Geographic expansion and acquisitions, particularly in Rest of World (RoW) markets, are key pillars to drive future growth.
Continued investment in complex generics, oligopeptides, drug delivery, and CAR-T therapies to fuel new growth avenues.
RoW business performing well with strong markets in Brazil, Canada, Egypt, and Saudi Arabia showing good growth potential.
Base domestic business expected to grow 8% to 10% with consistent secondary sales.

Margin guidance

Category 3

Natco expects more than 20% growth in earnings/profits for FY '25 given no major surprises.
Management is optimistic about achieving 15%+ top-line growth and around 20% profit growth.
Stable margins are anticipated if the product mix holds up over the next 1-2 years.
The base business PAT is expected to be around Rs. 200-250 crores annually, consistent with earlier guidance.
Natco aims to reinvent growth through niche Para-IV filings, geographic expansion, and acquisitions.
The Agrochemical business targets a 3x growth to Rs. 300 crores in the next 3 years.
The company anticipates sustaining Rs. 400 crore PAT per quarter over 1-2 years with a 5% tolerance.
Overall, management’s approach is conservative with estimates, expecting surprises but focusing on steady growth.

See what Natco Pharma Ltd management said on margin guidance — free account, 30 seconds.

Fundraise plans

Natco Pharma currently has Rs. 116 crores of debt, primarily comprising Rs. 40 crores EPC credit (non-prepayable) and Rs. 76 crores foreign discounting (self-liquidating).
On a net debt basis, the company is effectively net cash with Rs. 2,004 crores in cash, listed shares, investments, and deposits.
The debt is mainly for working capital, and management is not very concerned about it.
There is no explicit mention of any planned new fundraising through debt or equity in the near future.
The management is contemplating acquisitions and may consider buybacks depending on acquisition outcomes but has not committed to new equity or debt raises.
CAPEX plans of about Rs. 300 to 350 crores annually are to be funded from existing resources.
Overall, no immediate plans for new fundraising via debt or equity have been indicated.

Order book

- As per the transcript, Natco Pharma does not explicitly mention a current or expected order book or pending orders in exact figures. - The company highlighted strong ongoing business in Rest of World (RoW) markets with good orders from Egypt, Saudi Arabia, Brazil, and Canada. - Brazil direct exports and subsidiary exports are around $25-26 million annually; Canadian subsidiary sales near CAD 40 million. - The company is actively filing niche products, with ongoing confidence to file 2-3 first-to-file (FTF) products in coming years. - Business pipeline includes key product launches, including Semaglutide, Olaparib, Carfilzomib, Trabectedin, though litigations delay exact launch timelines. - The Crop Science division targets tripling business to Rs. 300 crores within 3 years, indicating expected growth and orders. - Working capital debt is effectively self-liquidating through receivables, reflecting healthy operational cash flow. No direct numeric order book data was disclosed.

See what Natco Pharma Ltd management said on order book — free account, 30 seconds.

Capex plans

Yes

The company plans a maintenance CAPEX of around Rs. 300 crores to Rs. 350 crores annually, mainly to maintain current operations and build orders. No large new site constructions are planned currently. (Page 18)
They are investing in complex generics, drug deliveries, oligopeptides, and CAR-T therapies as part of R&D and strategic innovation efforts. (Page 12)
Considering acquisitions primarily in the Rest of World (RoW) markets to strengthen the base business. No specific deals closed yet, but looking actively over the next few years. (Pages 5, 18)
Potential buyback considered if unable to close a large acquisition. (Page 4)
Exploring geographical expansion and niche filings along with acquisition as the three pillars for future growth. (Page 18)

Track Natco Pharma Ltd — get its next earnings analysis in your feed

How does Natco Pharma Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

ThisNatco Pharma Ltd

Rev 2Mar 3

See where Natco Pharma Ltd sits in Pharmaceuticals & BiotechnologySee which companies these are, and every other name in the sector.Open rankings

How does Natco Pharma Ltd rank in Pharmaceuticals & Biotechnology?

Compare Natco Pharma Ltd against every Pharmaceuticals & Biotechnology company (Q4 FY24) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

What Natco Pharma Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

Bajaj Healthcare (Q2 FY27)
Operating Margin: Operating Margin = (EBITDA / Revenue from operations) × 100 = (2,770.29 / 14,791.49) × 100 ≈ 18.73% . Key results statement takeaways from Baj
Himalaya Nutravedics (Q2 FY27)
Reported revenue from operations for FY26: ₹4,306.8 lakhs, a year-on-year increase of 105.1% from ₹2,099.7 lakhs in FY25 (Page 22, 14, 5, 4). Key investor prese
Granules India (Q2 FY27)
Granules plans to invest about ₹2,000 crore in organic capital expenditure over the next 3-4 years. Key concall takeaways from Granules India Ltd's Q2 FY27…
Bajaj Healthcare (Q2 FY26)
For HYE (Half Year Ending) Sept 2025, Total Income reported is ₹299.28 crore. Key investor presentation takeaways from Bajaj Healthcare Ltd's Q2 FY26 investor p

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →